<?xml version='1.0' encoding='utf-8'?>
<document id="29972633"><sentence text="Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers."><entity charOffset="31-39" id="DDI-PubMed.29972633.s1.e0" text="Apixaban" /><entity charOffset="45-57" id="DDI-PubMed.29972633.s1.e1" text="Cyclosporine" /><pair ddi="false" e1="DDI-PubMed.29972633.s1.e0" e2="DDI-PubMed.29972633.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29972633.s1.e0" e2="DDI-PubMed.29972633.s1.e1" /></sentence><sentence text="Apixaban is metabolized by cytochrome P450 (CYP) 3A4 in the liver and intestine, undergoes direct intestinal excretion, and is a substrate to permeability glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters"><entity charOffset="0-8" id="DDI-PubMed.29972633.s2.e0" text="Apixaban" /></sentence><sentence text=" We examined the drug interactions between cyclosporine and tacrolimus (combined inhibitors of CYP3A4, P-gp, and BCRP) with apixaban in 12 healthy adult male volunteers"><entity charOffset="43-55" id="DDI-PubMed.29972633.s3.e0" text="cyclosporine" /><entity charOffset="60-70" id="DDI-PubMed.29972633.s3.e1" text="tacrolimus" /><entity charOffset="124-132" id="DDI-PubMed.29972633.s3.e2" text="apixaban" /><pair ddi="false" e1="DDI-PubMed.29972633.s3.e0" e2="DDI-PubMed.29972633.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29972633.s3.e0" e2="DDI-PubMed.29972633.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29972633.s3.e0" e2="DDI-PubMed.29972633.s3.e2" /><pair ddi="false" e1="DDI-PubMed.29972633.s3.e1" e2="DDI-PubMed.29972633.s3.e1" /><pair ddi="false" e1="DDI-PubMed.29972633.s3.e1" e2="DDI-PubMed.29972633.s3.e2" /></sentence><sentence text=" Apixaban 10 mg was administered orally alone, in combination with 100 mg cyclosporine or 5 mg tacrolimus"><entity charOffset="1-9" id="DDI-PubMed.29972633.s4.e0" text="Apixaban" /><entity charOffset="74-86" id="DDI-PubMed.29972633.s4.e1" text="cyclosporine" /><entity charOffset="95-105" id="DDI-PubMed.29972633.s4.e2" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.29972633.s4.e0" e2="DDI-PubMed.29972633.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29972633.s4.e0" e2="DDI-PubMed.29972633.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29972633.s4.e0" e2="DDI-PubMed.29972633.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29972633.s4.e1" e2="DDI-PubMed.29972633.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29972633.s4.e1" e2="DDI-PubMed.29972633.s4.e2" /></sentence><sentence text=" Co-administration with cyclosporine resulted in increase in apixaban maximum plasma concentration (Cmax ) and area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUC(0-tlast) ) with associated geometric mean ratios (GMRs) and 90% confidence intervals (CIs) of 143% (112, 183) and 120% (97, 148), respectively"><entity charOffset="24-36" id="DDI-PubMed.29972633.s5.e0" text="cyclosporine" /></sentence><sentence text=" Co-administration with tacrolimus resulted in reduction in apixaban Cmax and AUC(0-tlast) with associated GMRs (90% CI) of 87% (69, 112) and 78% (63, 97), respectively"><entity charOffset="24-34" id="DDI-PubMed.29972633.s6.e0" text="tacrolimus" /></sentence><sentence text=" The observed changes in apixaban exposure margins with cyclosporine or tacrolimus are within the range of the historical clinical development program, therefore, apixaban dose adjustments are not warranted"><entity charOffset="25-33" id="DDI-PubMed.29972633.s7.e0" text="apixaban" /><entity charOffset="56-68" id="DDI-PubMed.29972633.s7.e1" text="cyclosporine" /><entity charOffset="72-82" id="DDI-PubMed.29972633.s7.e2" text="tacrolimus" /><entity charOffset="163-171" id="DDI-PubMed.29972633.s7.e3" text="apixaban" /><pair ddi="false" e1="DDI-PubMed.29972633.s7.e0" e2="DDI-PubMed.29972633.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29972633.s7.e0" e2="DDI-PubMed.29972633.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29972633.s7.e0" e2="DDI-PubMed.29972633.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29972633.s7.e0" e2="DDI-PubMed.29972633.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29972633.s7.e1" e2="DDI-PubMed.29972633.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29972633.s7.e1" e2="DDI-PubMed.29972633.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29972633.s7.e1" e2="DDI-PubMed.29972633.s7.e3" /><pair ddi="false" e1="DDI-PubMed.29972633.s7.e2" e2="DDI-PubMed.29972633.s7.e2" /><pair ddi="false" e1="DDI-PubMed.29972633.s7.e2" e2="DDI-PubMed.29972633.s7.e3" /></sentence><sentence text="" /></document>